Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/20/25
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend YieldSeeking Alpha • 11/20/25
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SCZacks Investment Research • 11/20/25
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?The Motley Fool • 11/20/25
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV TreatmentBenzinga • 11/19/25
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another StudyZacks Investment Research • 11/19/25
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 InfectionBusiness Wire • 11/19/25
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European UnionBusiness Wire • 11/19/25
Why biotech and drug stocks are on the mend even though the rest of the market is hurtingMarket Watch • 11/18/25
Drug Giant Merck Breaks Out Past New Buy Point; CME, Marathon Eye EntriesInvestors Business Daily • 11/18/25
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart ConditionBenzinga • 11/18/25
Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)Business Wire • 11/18/25
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026Zacks Investment Research • 11/17/25
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 11/17/25